CBIO
Crescent Biopharma, Inc.
NASDAQ · USHealthcareBiotechnology
$15.05+2.03%
Price as of Jul 20, 2026
CBIO capital
Crescent Biopharma, Inc. capital & dividend
Leverage, liquidity, debt coverage and shareholder-distribution metrics.
Leverage
- Debt / equity
- 0.01x
- Net debt / equity
- -1.02x
- Debt / assets
- 0.01x
- Debt / EBITDA
- -0.01x
- Net debt / EBITDA
- 1.18x
Liquidity & coverage
- Current ratio
- 13.78x
- Quick ratio
- 13.78x
- Cash ratio
- 13.33x
- Interest coverage
- -152.04x
- EBITDA / interest
- -148.05x
- Working capital
- $181.4M
Cash & dividend
- FCF / debt
- -92.47x
- Cash flow / debt
- -45.12x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.